June 8, 2022

The MMS will continue to monitor developments related to the coronavirus (COVID-19) and the response by state and federal agencies. For current information, including updates from NEJM, visit the dedicated page on the MMS website: massmed.org/covid-19.

Practice Management

Pre-ordering information for Pfizer (6 months to 4) and Moderna (6 months to 5) pediatric vaccine formulations

Massachusetts COVID-19 Vaccine Program (MCVP) enrolled provider sites are now able to place pre-orders for the new formulations of the COVID vaccine through the Massachusetts Immunization Information System (MIIS). For guidance on how to place COVID-19 vaccine orders in the MIIS please see mini-guide | Flu/COVID-19 order.

- Pfizer (maroon cap) - NDC 59267-0078-04
  - For 6 months to 4 years old.
  - Vaccines will ship at -80°C, like all current Pfizer COVID-19 vaccines.
  - Vaccines can be stored in the ultracold freezer for 12 months after manufacturer date and 10 weeks in the refrigerator. **Do not store in the freezer.**

- Moderna (blue cap) - NDC 80777-0279-99
  - For 6 months to 5 years old.
- Vaccines will ship at -20°C, like all current Moderna COVID-19 vaccines.
- Vaccines can be stored in the freezer until the expiration date or in the refrigerator for 30 days.

The packaging configuration for both vaccine products is 10-dose vials in cartons of 10 vials with a minimum order quantity of 100 doses. Orders for these formations placed after June 7 will begin being delivered on Thursday, June 23rd, and throughout the rest of that week and into the following week. Please note shipping dates are estimated and based on US Food and Drug Administration (FDA) emergency use authorization (EUA) of these new formulations on June 15 with subsequent Centers for Disease Control and Prevention (CDC) approval immediately after. If there are any delays in these approvals at the federal level the above estimated shipping dates will be delayed. Practices may contact the Vaccine Management Unit at 617-983-6828 with any questions.

---

**Public Health**

**CDC's interactive tool is intended to help users assess the need for booster doses of COVID-19 vaccine**

A new interactive tool launched by the Centers for Disease Control and Prevention (CDC) is intended to help users identify whether they (or someone else) need to receive a booster dose of COVID-19 vaccine. The “COVID-19 Vaccine Boosters” tool asks a series of simple questions about age, immunocompromise, number and type of previous doses of COVID-19 vaccines, and how long ago they received the most recent vaccination. From these answers, the tool reports whether a first or second booster dose may be beneficial and presents considerations for when to receive it. To see the tool, [click here](#).

---

**CDC alert on COVID-19 rebound after Paxlovid**

The Centers for Disease Control and Prevention (CDC) in late May issued an alert about potential recurrence of COVID-19 in patients who have taken Paxlovid. The rebound is reported to occur between 2 and 8 days after initial recovery. It is characterized by a recurrence of COVID-19 symptoms or a new positive viral test after having tested
negative. People with a recurrence of COVID-19 symptoms, or a new positive test after having tested negative, should isolate again for at least five days and should wear a mask for a total of 10 days after symptoms start. The CDC continues to recommend Paxlovid for patients at high risk for serious complications from infection. There is currently no evidence that additional treatment is needed with Paxlovid or other anti-SARS-CoV-2 therapies where COVID-19 rebound is suspected. To read more, click here.